Limited sensitivity of patient-derivedCAFs to 212 Pb-FAP-targeted radionuclide therapy: implications for stromal targeting in radiopharmaceutical therapy (EANM 2026) - Sep 29, 2026 - Abstract #OP-797; Pres time: Oct 21, 2026; 08:00 AM - 09:30 AM; Location: Hall B; " FAP-2286 was successfully radiolabelled with 212Pb, achieving radiochemical purity ≥97%... Patientderived lung CAFs exhibited limited sensitivity to FAPTRT despite confirmed radioligand uptake, suggesting possible radioresistance under the tested conditions. The observed transient stress response without sustained DNA damage or cell death suggests that CAF-targeted radionuclide therapy may not achieve direct stromal depletion under these conditions. These findings highlight a potential limitation of FAP-TRT and underscore the need to evaluate nonlethal CAF responses."
Clinical • Stroma • Lung Cancer • Solid Tumor • CAFs • CDKN1A • FAP • PDGFRB • PDPN • VIM
|
|
S. Kvarsvik Kristiansen 1, 2; I. Z. Martinez 3; A. Juzeniene 1, 2
|